Dengyong Zhang | Cancer Cell Biology | Best Researcher Award

Posted on by sciencefather

Prof. Dengyong Zhang | Cancer Cell Biology | Best Researcher Award

Prof. Dengyong Zhang , The First Affiliated Hospital of Bengbu Medical university , China

Zhang Deng Yong is a highly accomplished medical professional and researcher specializing in hepatocellular carcinoma and cholangiocarcinoma. Born in Liu’an, Anhui Province, China, in 1989, he currently works as an attending doctor at the First Affiliated Hospital of Bengbu Medical College. Dr. Zhang earned his Bachelor’s and Master’s degrees from Bengbu Medical College and is currently pursuing a Doctor’s degree at Anhui Medical University. He is also a visiting scholar at MD Anderson Cancer Center. With an extensive portfolio of research, Dr. Zhang is known for his significant contributions to the study of cancer biology, particularly in liver and biliary cancers. His commitment to medical research and patient care positions him as a key figure in the field of oncology.

Publication Profile:

Scopus

Strengths for the Award:

Dr. Zhang Deng Yong exhibits exceptional skills and commitment to the field of medical research, particularly in oncology. His advanced academic qualifications (Doctor’s degree from Anhui Medical University and a Master’s degree from Bengbu Medical College) provide a solid foundation for his innovative research. He has made significant contributions to understanding the molecular mechanisms underlying various cancers, especially hepatocellular carcinoma and cholangiocarcinoma, as evidenced by his numerous impactful publications. His collaborative work, demonstrated through his visiting scholar position at the MD Anderson Cancer Center, speaks to his ability to engage in high-caliber research environments.

Areas for Improvement:

While Dr. Zhang’s research portfolio is robust, expanding his involvement in interdisciplinary research or establishing collaborations beyond oncology could open new avenues in cancer treatment and prevention. Additionally, enhancing his focus on translational medicine could bridge the gap between laboratory research and clinical application.

Education:

Dr. Zhang Deng Yong’s academic journey began at Bengbu Medical College, where he earned his Bachelor’s degree in Medicine (2007-2012). He furthered his education with a Master’s degree in Surgery from the same institution (2012-2015). Currently, he is pursuing a Doctor’s degree at Anhui Medical University (2021-2024), specializing in oncology and cancer treatment. His dedication to academic excellence is reflected in his continued involvement in both teaching and advanced clinical research. In addition to his formal education, Dr. Zhang has participated in various international conferences and academic collaborations, further strengthening his expertise in medical research and surgery.

Experience:

Dr. Zhang has a solid background in clinical practice and research. Since 2016, he has served as an attending doctor at the First Affiliated Hospital of Bengbu Medical College, where he specializes in oncology and surgery. He also worked as a resident at Lu’an Traditional Chinese Medicine Hospital from 2015 to 2016. In 2022, Dr. Zhang had the opportunity to enhance his research experience as a visiting scholar at MD Anderson Cancer Center, a leading institution in cancer research. His clinical experience, combined with his academic training, allows him to offer patients the highest standard of care while contributing to groundbreaking cancer research. His expertise in hepatocellular carcinoma and cholangiocarcinoma has made him a sought-after expert in his field.

Awards and Honors:

Dr. Zhang Deng Yong’s commitment to research and medicine has earned him various recognitions and funding opportunities. He was awarded a Natural Science Fund of Anhui Province support from 2018 to 2020. Additionally, his work has been widely recognized in the academic community, where he has acted as a reviewer for multiple prestigious journals such as Oncology Reports, Molecular Medicine Reports, Oncology Letters, and Experimental and Therapeutic Medicine. These roles reflect his standing in the medical and scientific community. His involvement in clinical and research innovation has placed him at the forefront of oncology research, especially in the areas of hepatocellular carcinoma and cholangiocarcinoma.

Research Focus:

Dr. Zhang’s research primarily focuses on cancer biology, particularly hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA). He is dedicated to understanding the molecular mechanisms behind cancer progression, immune responses, and therapeutic resistance. His work includes investigating the roles of various genetic and epigenetic factors in the development of liver and biliary cancers, as well as identifying potential biomarkers for early diagnosis and prognosis. Dr. Zhang’s research extends to exploring novel therapeutic approaches, including immunotherapy, targeted therapies, and the use of CRISPR technology. His publications also delve into the immune landscape and molecular pathways that influence cancer progression, with an emphasis on improving patient outcomes through precision medicine. His passion for cancer research and patient care continues to drive his work and innovations in the field.

Publications Top Notes:

  1. Immunosenescence and immunotherapy in elderly patients with hepatocellular carcinoma 🧬🦠

  2. USP1 promotes cholangiocarcinoma progression by deubiquitinating PARP1 to prevent its proteasomal degradation 🧬⚡

  3. CRISPR screening identifies BET and mTOR inhibitor synergy in cholangiocarcinoma through serine glycine one carbon 🔬🧬

  4. MiR-186-5p prevents hepatocellular carcinoma progression by targeting methyltransferase-like 3 that regulates m6A-mediated stabilization of follistatin-like 5 💡🧬

  5. The COL7A1/PI3K/AKT axis regulates the progression of cholangiocarcinoma 🔬🧬

  6. Integrative analysis of bulk and single-cell transcriptomic data reveals novel insights into lipid metabolism and prognostic factors in hepatocellular carcinoma 🧬💡

  7. HSDL2 knockdown promotes the progression of cholangiocarcinoma by inhibiting ferroptosis through the P53/SLC7A11 axis ⚡🔬

  8. Application of mesohepatectomy with caudate lobectomy for the treatment of type III–IV hilar cholangiocarcinoma: a single-center retrospective study 🏥📑

  9. Prognostic model for hepatocellular carcinoma based on anoikis-related genes: immune landscape analysis and prediction of drug sensitivity 🔬💉

  10. Bile metabolites as diagnostic biomarkers for perihilar cholangiocarcinoma 🧬💡

Conclusion:

Dr. Zhang Deng Yong’s expertise in cancer research, particularly his contributions to hepatocellular carcinoma and cholangiocarcinoma, places him as a strong contender for the Research for Best Researcher Award. His dedication to advancing medical knowledge, coupled with his impressive list of publications and international collaboration, makes him an invaluable asset to the scientific community. With continued growth in clinical application, Dr. Zhang is poised for further recognition and impactful contributions to medical research.

 

 

 

Xue Li | Cancer Cell Biology | Best Researcher Award

Posted on by sciencefather

Dr. Xue Li | Cancer Cell Biology | Best Researcher Award

Dr. Xue Li , Institute of Chemistry Chinses Academy of Sciences , China

Dr. Xue Li is an Assistant Researcher at the Institute of Chemistry, Chinese Academy of Sciences, specializing in the design and application of functional carbon nanomaterials in biomedical fields. She holds a Bachelor’s degree from Sichuan University (2009-2013) and a PhD from the Institute of Chemistry, Chinese Academy of Sciences (2013-2018). Since 2018, Dr. Li has contributed significantly to the development of nanomaterial-based therapies for various diseases, particularly focusing on cancer, diabetes, and neurodegenerative diseases. Her work is characterized by innovative approaches to developing fullerene-based nanoparticles for therapeutic purposes. Dr. Li has published extensively in high-impact journals and is a recognized leader in her field, collaborating with national and international experts to drive forward the potential of nanomaterials in medicine.

Publication Profile:

Orcid

Strengths for the Award:

Dr. Xue Li stands out for her groundbreaking research on the design and biomedical application of functional carbon nanomaterials, particularly fullerenes, for treating complex diseases. Her work explores innovative therapeutic strategies, such as targeting inflammation, oxidative stress, and immune responses to address conditions like cancer, diabetes, and neurodegenerative diseases. Dr. Li has authored multiple high-impact journal publications, demonstrating her deep expertise in nanomaterials and their integration into medical treatments. Her contributions, such as reducing neuroinflammation to alleviate Parkinson’s disease and mitigating immune-mediated liver injury, showcase her ability to translate scientific knowledge into real-world solutions. Dr. Li’s collaborative approach and her role in advancing nanomedicine highlight her as a leading figure in her field.

Areas for Improvement:

While Dr. Li’s work is exceptional, expanding her research into more diverse therapeutic areas, such as cardiovascular diseases or neurodegenerative conditions like Alzheimer’s, could further broaden the impact of her research. Additionally, exploring the scalability and commercialization of her nanomaterial-based therapies would be a valuable direction for future development.

Education:

Dr. Xue Li completed her Bachelor’s degree in Chemistry at Sichuan University in June 2013. She pursued her Ph.D. at the Institute of Chemistry, Chinese Academy of Sciences, from 2013 to 2018, focusing on the design and application of nanomaterials, particularly fullerenes, for medical applications. During her doctoral studies, she gained significant experience in the synthesis, functionalization, and biomedical use of carbon nanomaterials. Dr. Li’s research laid the foundation for her current work as an Assistant Researcher at the Institute of Chemistry, Chinese Academy of Sciences, a position she has held since 2018.

Experience:

Dr. Xue Li has worked extensively in the field of nanomaterials, contributing to significant advancements in the application of fullerene-based nanoparticles for biomedical purposes. Since 2018, she has been an Assistant Researcher at the Institute of Chemistry, Chinese Academy of Sciences, where her research focuses on the development of functional nanomaterials for the treatment of diseases such as cancer, diabetes, and neurodegenerative disorders. Dr. Li has worked on several high-impact projects, including designing inflammation-targeting nanoparticles and investigating their roles in regulating immune responses and improving disease outcomes. Her experience spans both experimental techniques in nanomaterial synthesis and in vivo therapeutic applications. Additionally, Dr. Li has collaborated with multiple research institutions globally and has been recognized for her contributions to advancing nanomedicine.

Research Focus:

Dr. Xue Li’s research focuses on the design, synthesis, and biomedical applications of functional carbon nanomaterials, particularly fullerenes and their derivatives. Her work aims to develop innovative therapeutic strategies, leveraging the unique properties of these nanomaterials to address complex medical challenges, including cancer, autoimmune diseases, and neurodegenerative disorders. She is particularly interested in creating nanoparticles that target specific cellular pathways, such as inflammation and oxidative stress, to improve therapeutic outcomes. Dr. Li’s research includes the development of nanoparticles that can modulate macrophage differentiation and mitigate conditions like rheumatoid arthritis, autoimmune hepatitis, and neuroinflammation. By focusing on the functionalization of fullerenes, her work also explores how these materials can be used to treat insulin resistance and neurodegenerative diseases such as Parkinson’s.

Publications Top Notes:

  1. 🧬 Fullerenols hijack lysosomes to disrupt inter-organellar crosstalk and block autophagy pre-activated by mTOR inhibitors for cancer cell PANoptosis. Sci. Bull. 2025
  2. 💊 Inflammation-targeting fullerene nanoparticles dually inhibit macrophage and osteoclast differentiation for mitigating rheumatoid arthritis. CCS Chem. 2024
  3. 🔬 Curdlan decorated fullerenes mitigate immune-mediated hepatic injury for autoimmune hepatitis therapeutics via reducing macrophage infiltration. ACS Appl. Mater. Interfaces 2024
  4. 💡 The application of nanomaterials in the treatment of pancreatic-related diseases. Int. J. Mol. Sci. 2024
  5. 🧠 Oral [60] fullerene reduces neuroinflammation to alleviate Parkinson’s disease via regulating gut microbiome. Theranostics 2023
  6. 🍏 Dual regulation on oxidative stress and endoplasmic reticulum stress by [70] fullerenes for reversing insulin resistance in diabetes. Nano Today 2022
  7. 🔬 Gadofullerene Nanoparticles Extend Survival Rate and Down-Regulate Thrombin Expression in Orthotopic Pancreatic Cancer. Sci. China Mater. 2022
  8. 🩸 Gadofullerene Nanoparticles Reverse Dysfunctions of Pancreas and Improve Hepatic Insulin Resistance for Type 2 Diabetes Mellitus Treatment. ACS Nano 2019
  9. 🌱 Biomaterials: Application of Nanomaterials in the Treatment of Pancreatic-Related Diseases. Biomaterials 2018

Conclusion:

Dr. Xue Li’s exceptional research on functional nanomaterials and their applications in medicine, particularly in cancer, autoimmune diseases, and neurodegeneration, makes her a strong contender for the Research for Best Researcher Award. Her innovative approaches, contributions to high-impact journals, and dedication to advancing nanomedicine provide a solid foundation for future breakthroughs.